As METTL3 is an m 6 A methyltransferase, we are very curious whether METTL3 regulates mRNA m 6 A methylation of SLC7A11 and FSP1 to affect their protein expression
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906
These results provide us confidence to initiate MARITIME, a Phase III program across obesity and a number of related conditions, providing a unique potential new treatment option for patients. MariTide was well-tolerated across all dosage groups, with the most common side effects being mild gastrointestinal symptoms, such as nausea and diarrhea, which were largely mild, transient and primarily associated with the first dose, according to Amgen
These findings support its potential as a promising therapeutic candidate for NAFLD (88)
A Profit oferece aqui uma opo acessvel e confivel para quem quer iniciar sua jornada com a L-Carnitina, permitindo avaliar os resultados antes de adquirir embalagens maiores
Terasaki for providing TR-BBB cell lines and Novartis International Pharmaceutical Ltd